Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Clinical and Molecular Hepatology ; : 411-415, 2012.
Article Dans Anglais | WPRIM | ID: wpr-15268

Résumé

Erythropoietic protoporphyria (EPP) is an inherited disorder of the heme metabolic pathway that is characterized by accumulation of protoporphyrin in the blood, erythrocytes, and tissues, and cutaneous manifestations of photosensitivity, all resulting from abnormalities in ferrochelatase (FECH) activity due to mutations in the FECH gene. Protoporphyrin is excreted by the liver, and excess protoporphyrin leads to cholelithiasis with obstructive episodes and chronic liver disease, finally progressing to liver cirrhosis. Patients with end-stage EPP-associated liver disease require liver transplantation. We describe here a 31-year-old male patient with EPP who experienced acute-on-chronic liver failure and underwent deceased-donor liver transplantation. Surgical and postoperative care included specific shielding from exposure to ultraviolet radiation to prevent photosensitivity-associated adverse effects. The patient recovered uneventfully and was doing well 24 months after transplantation. Future prevention and treatment of liver disease are discussed in detail.


Sujets)
Adulte , Humains , Mâle , Maladie aigüe , Maladie du foie en phase terminale/étiologie , Ferrochelatase/génétique , Cirrhose du foie/diagnostic , Transplantation hépatique , Mutation , Protoporphyrie érythropoïétique/complications
2.
The Korean Journal of Hepatology ; : 83-88, 2010.
Article Dans Anglais | WPRIM | ID: wpr-98606

Résumé

Erythropoietic protoporphyria (EPP) is a rare disorder of heme biosynthesis caused by mutations in the gene encoding the enzyme ferrochelatase. In EPP, deficient ferrochelatase activity leads to the excessive production and biliary excretion of protoporphyrin (PP). The major clinical features of EPP are photosensitivity and hepatobiliary disease that may progress to severe liver disease, that are caused by the toxicity of PP. EPP-related liver disease has been treated medically or surgically including liver transplantation. We described a 20-year-old male with severe liver disease who was diagnosed with EPP based on clinical and laboratory findings. He was treated with cholestyramine resin. Six months after the treatment, he was doing well without any abdominal pain or photosensitivity.


Sujets)
Humains , Mâle , Jeune adulte , Bilirubine/sang , Résine de cholestyramine/usage thérapeutique , Oedème/complications , Érythème/complications , Ferrochelatase/génétique , Maladies du foie/complications , Protoporphyrie érythropoïétique/complications , Protoporphyrines/métabolisme
SÉLECTION CITATIONS
Détails de la recherche